Cite

    Stephen Gardner et al.. “A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects.” Liver international, vol. 34, n.d., pp. e89–e95. http://access.bl.uk/ark:/81055/vdc_100024856717.0x00001b